- 专利标题： Crystalline form of lenvantinib mesylate and process of preparation thereof
-
申请号： US16364114申请日： 2019-03-25
-
公开(公告)号： US10562855B2公开(公告)日： 2020-02-18
- 发明人: Minhua Chen , Yanfeng Zhang , Xiaojuan Diao , Xiaoyu Zhang
- 申请人： CRYSTAL PHARMATECH CO., LTD.
- 申请人地址： CN Suzhou, Jiangsu
- 专利权人： CRYSTAL PHARMATECH CO., LTD.
- 当前专利权人： CRYSTAL PHARMATECH CO., LTD.
- 当前专利权人地址： CN Suzhou, Jiangsu
- 代理机构： VLP Law Group LLP
- 代理商 Kent H. Cheng
- 主分类号： C07D215/48
- IPC分类号： C07D215/48 ; C07D215/233 ; A61P35/00
摘要：
The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.
公开/授权文献
信息查询
